Evidence map›Paper›PMID 38276624›Full record

ArticleMolecules (Basel, Switzerland)2024

Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody.

Ying Zheng, Guifang Dou, Shuchen Liu, Zhiyun Meng, Eric I Tsao, Gang Yu, Xiaoxia Zhu, Ruolan Gu, Zhuona Wu, Yunbo Sun and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Ying ZhengDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.ORCID 0000-0001-7455-0951
Guifang DouDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.ORCID 0000-0001-5004-2194
Shuchen LiuDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Zhiyun MengDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Eric I TsaoSynermore Biologics Co., Ltd., Suzhou 215000, China.
Gang YuState Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Xiaoxia ZhuDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Ruolan GuDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Zhuona WuDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Yunbo SunDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Peng HanDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Hui GanDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNUS Biologic (United States) · US

Funding

Beijing Municipal Natural Science Foundation No. 7202148
6 · The paper itself

Abstract

LR004 is a novel chimeric (human/mouse) monoclonal antibody developed for the treatment of advanced colorectal carcinoma with detectable epidermal growth factor receptor (EGFR) expression. We aimed to investigate the preclinical pharmacokinetics (PK) and in vivo biodistribution of LR004. The PK profiles of LR004 were initially established in rhesus monkeys. Subsequently,

Indexed as

Antineoplastic AgentsColorectal NeoplasmsAnimalsAntibodies, MonoclonalCell Line, TumorErbB ReceptorsHumansMiceTissue DistributionAntibodies, MonoclonalAntineoplastic AgentsErbB ReceptorsEGFRmonoclonal antibodynanoSPECT/CTpharmacokineticsradionuclide-based biodistributiontumor-targeting

Identifiers

PMID38276624
PMCPMC10821095
OpenAlexW4391100469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.